US · Healthcare · Drug Manufacturers - General
EPS came in at 8.38 against a street estimate of 6.01 — a beat of 39.4%.
Analysts rate Eli Lilly and Company a buy (24 buy, 5 hold, 2 sell out of 31) with an average price target of $1,324.87.
CONFIDENT LLY crushed Q2 with 48% revenue growth, raised FY26 guidance by $2.5B, and announced major pipeline wins including retatrutide Phase III data and Foundayo oral obesity drug expanding globally. Q2 2026 Europe +55% constant currency; China +93% driven by Mounjaro uptake; Japan +30%; Rest of World +136%. Mounjaro global market leader at ~55% share. Analysts pressed on Foundayo U.S. deceleration vs. international, retatrutide regulatory pathway (BLA vs. NDA), and net pricing dynamics. Management emphasized early-stage data noise, FDA engagement on BLA pathway, and confident guidance despite Q3-Q4 seasonal headwinds. 2026-08-05…
Full summary in the app.
| Fund | Stake |
|---|---|
| Lilly Endowment Inc | 10.14% |
| BlackRock Inc | 7.45% |
| Vanguard Capital Management, LLC | 5.99% |
| PNC Financial Services Group Inc | 5.76% |
| State Street Corp | 4.00% |
| FMR Inc | 2.96% |
| Vanguard Portfolio Management, LLC | 2.35% |
| Capital Research Global Investors | 2.34% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 ELI LILLY AND COMPANY – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue Q2 2026: $22,974 million (up 48% vs Q2 2025: $15,558 million) • Revenue H1 2 | 2026-08-05 |
| Results announced · Q3 2026 ELI LILLY Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 revenue: $23.0 billion, up 48% year-over-year • Q2 2026 reported EPS: $7.94, up 26% (i | 2026-08-05 |
| Company announcement · Q2 2026 ELI LILLY AND COMPANY - 8-K SUMMARY HEADLINE NUMBERS • Total debt offering completed: $8.94 billion net proceeds (after underwriting discounts, befo | 2026-05-20 |
| Shareholder vote results · Q2 2026 ELI LILLY AND COMPANY – FORM 8-K SUMMARY Annual Meeting of Shareholders (May 4, 2026) --- HEADLINE NUMBERS • Total shares voted: 847,254,010 shares | 2026-05-07 |
| Quarterly report · Q1 2026 ELI LILLY AND COMPANY – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $19,799 million (Q1 2026) vs. $12,729 million (Q1 2025) — 55.6% increase • | 2026-04-30 |
| Results announced · Q2 2026 ELI LILLY Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q1 2026 revenue: $19.8 billion, up 56% year-over-year • Reported EPS: $8.26, up 170% from $3.0 | 2026-04-30 |
| Proxy statement · Q1 2026 ELI LILLY AND COMPANY - 2026 PROXY STATEMENT SUMMARY CEO COMPENSATION David Ricks (CEO, President, Chair) - Total compensation details not specified | 2026-03-20 |
| Annual report FY2025 ELI LILLY AND COMPANY - 2025 ANNUAL REPORT SUMMARY HEADLINE NUMBERS • Market capitalization (as of last business day of Q2 2025): approximately $807 | 2026-02-12 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $1.73 / share ex-date Aug 14, 2026 · pay Sep 10, 2026 | 2026-08-14 |
| Dividend | $1.73 / share ex-date May 15, 2026 · pay Jun 10, 2026 | 2026-05-15 |
| Dividend | $1.73 / share ex-date Feb 13, 2026 · pay Mar 10, 2026 | 2026-02-13 |
| Dividend | $1.50 / share ex-date Nov 14, 2025 · pay Dec 10, 2025 | 2025-11-14 |
| Dividend | $1.50 / share ex-date Aug 15, 2025 · pay Sep 10, 2025 | 2025-08-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Eli Lilly and Company — free to start.
Google PlayApp StoreData updated 2026-09-18.